is bpc 157 wada approved Rules and Risks of BPC-157 for Athletes and Military Service Members BPC-157 FDA Approval Status 2026:

Retatrutide is a peptide agonist with an extended half-life (~6 days), allowing for weekly subcutaneous administration

Footnotes Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed

it is descriptive of what the literature and protocol structure suggest, not a promise of results

The importance of education Rogan's podcast discussions have educated millions about peptides, but he's clear that podcast entertainment isn't medical advice

Hoping you are not fighting a virus

Acknowledgements The authors are supported by National Institute of Diabetes and Digestive and Kidney Disease grants R01DK61931 and R01DK68271 (J.R.T.), U.S